Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review - INRAE - Institut national de recherche pour l’agriculture, l’alimentation et l’environnement Access content directly
Journal Articles British Journal of Pharmacology Year : 2024

Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review

Stavros Topouzis
Steve Alexander
Claudio Mauro
Hemal Patel
Gary Stephens
Xin Wang
Péter Ferdinandy

Abstract

Abstract In 2023, seventy novel drugs received market authorization for the first time in either Europe (by the EMA and the MHRA) or in the United States (by the FDA). Confirming a steady recent trend, more than half of these drugs target rare diseases or intractable forms of cancer. Thirty drugs are categorized as “first‐in‐class” (FIC), illustrating the quality of research and innovation that drives new chemical entity discovery and development. We succinctly describe the mechanism of action of most of these FIC drugs and discuss the therapeutic areas covered, as well as the chemical category to which these drugs belong. The 2023 novel drug list also demonstrates an unabated emphasis on polypeptides (recombinant proteins and antibodies), Advanced Therapy Medicinal Products (gene and cell therapies) and RNA therapeutics, including the first‐ever approval of a CRISPR‐Cas9‐based gene‐editing cell therapy.
Fichier principal
Vignette du fichier
British J Pharmacology - 2024 - Papapetropoulos - Novel drugs approved by the EMA the FDA and the MHRA in 2023 A year in.pdf (3.58 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Licence : CC BY - Attribution

Dates and versions

hal-04533844 , version 1 (05-04-2024)

Licence

Attribution

Identifiers

Cite

Andreas Papapetropoulos, Stavros Topouzis, Steve Alexander, Miriam Cortese-Krott, Dave Kendall, et al.. Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review. British Journal of Pharmacology, 2024, ⟨10.1111/bph.16337⟩. ⟨hal-04533844⟩
31 View
2 Download

Altmetric

Share

Gmail Facebook X LinkedIn More